Jonathan T. Yang

Phase 1a clinical trial of XRD-0394, a first-in-class dual ATM/DNA-PK inhibitor, in combination with palliative radiotherapy

Christopher T. Chen, Michael F. Gensheimer, Tona M. Gilmer, Jennifer Stanley et autres

PURPOSE: XRD-0394 is a dual ATM/DNA-PK inhibitor designed to increase tumor radiosensitivity. We evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single-dose XRD-0394 administered with palliative radiotherapy (RT) in a first-in-human trial. PATIENTS AND METHODS: In an open-label, multicenter phase 1a …

us, ca (code pays fourni par la source)

A Phase I Study of Cyclical Hypofractionated Palliative Radiation Therapy (Quad Shot) for Central Lung Tumors in Patients With Stage IV Non-Small Cell Lung Cancer: Results From the PROMISE 006 Trial

Y. Helen Zhang, Afsheen Iqbal, Daphna Gelblum, Jennifer Ma et autres

us (code pays fourni par la source)

Supplementary fig 1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Supplement Figure 1. Survival analysis for cohort. Overall survival (median=9 months) for the whole cohort is shown with a 95% confidence interval (blue).

Supplementary fig 3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Supplemental Figure 3. Tumor purity estimates by FACETS in plasma and CSF samples (n=11, plasma; n=32, CSF, Wilcoxon rank sum test p=0.001)

Supplementary fig 4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Supplemental Figure 4. The distribution of clonal and subclonal alterations in CSF ctDNA pre and post-pCSI.

Supplementary fig 2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Supplemental Figure 2. Compartment analysis comparing altered genes in solid tumors, plasma ctDNA, and CSF ctDNA, pre and post-pCSI.

Supplementary fig 5 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Supplemental Figure 5. Concordance between plasma and CSF ctDNA variants over time.

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Gene set enrichment analysis

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Alterations called after MSK-IMPACT

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

CNS and systemic disease status for each patient

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Neil Ari Wijetunga, Alexander G. Goglia, Nils Weinhold, Michael F. Berger et autres

Read sequencing depth by sample

TIP-15. Trial in progress: phase IB study of concurrent Azeliragon, a RAGE inhibitor, with craniospinal irradiation in patients with leptomeningeal metastases

K.M. Banson, Judith D. Goldberg, Benjamin Thomas Cooper, Joshua Seth Silverman et autres

Abstract Leptomeningeal metastases (LM) can cause debilitating neurologic symptoms and are associated with a poor prognosis. Compared to involved-field radiation therapy, craniospinal irradiation (CSI) improves progression free survival and overall survival. Recent studies have shown that inhibiting the receptor for advanced glycation …

us (code pays fourni par la source)